Precision BioSciences, Inc.
PBGENE-DMD
Duchenne muscular dystrophy
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for PBGENE-DMD in Duchenne muscular dystrophy are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“The Company has the goal of activating the first clinical site in the U.S. in the first half of 2026.”